Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deepu Madduri

Showing results (11-20 of 50) with videos related to

Pageof 5
Sort By:
Expert Review of Hematology|December 17, 2020
A comprehensive overview of daratumumab and carfilzomib and the recently approved daratumumab, carfilzomib and dexamethasone regimen in relapsed/refractory multiple myelomaShambavi Richard, Sundar Jagannath, Hearn Jay Cho, et al.
Frontiers in Immunology|December 1, 2018
Blood Transfusion Management for Patients Treated With Anti-CD38 Monoclonal AntibodiesGuido Lancman, Suzanne Arinsburg, Jeffrey Jhang, et al.
Expert Review of Hematology|August 1, 2020
Immunomodulatory drug- and proteasome inhibitor-backbone regimens in the treatment of relapsed multiple myeloma: an evidence-based reviewLarysa Sanchez, Kevin Barley, Joshua Richter, et al.
Therapeutic Advances in Hematology|February 22, 2021
Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myelomaLarysa Sanchez, Joshua Richter, Hearn Jay Cho, et al.
Clinical Advances in Hematology & Oncology : H&O|December 5, 2017
The effect of novel therapies in high-molecular-risk multiple myelomaGuido Lancman, Douglas Tremblay, Kevin Barley, et al.
Blood Advances|June 28, 2018
Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modelingVernon Wu, Erin Moshier, Siyang Leng, et al.
Blood Cancer Discovery|October 18, 2021
Bispecific Antibodies in Multiple Myeloma: Present and FutureGuido Lancman, Dahniel L Sastow, Hearn J Cho, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 15, 2021
Efficacy of Intravenous Immunoglobulin for Preventing Infections in Patients with Multiple MyelomaGuido Lancman, Katleen Lozada, Nida Athar, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 15, 2020
Timing of Autologous Stem Cell Transplantation for Multiple Myeloma in the Era of Current TherapiesSiyang Leng, Erin Moshier, Douglas Tremblay, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 18, 2021
Optimal Supportive Care With Selinexor Improves Outcomes in Patients With Relapsed/Refractory Multiple MyelomaAjai Chari, Erika Florendo, Ines Stefania Mancia, et al.
Pageof 5

Showing results (11-20 of 50) with videos related to

Sort By:
Pageof 5
Expert Review of Hematology|December 17, 2020
A comprehensive overview of daratumumab and carfilzomib and the recently approved daratumumab, carfilzomib and dexamethasone regimen in relapsed/refractory multiple myelomaShambavi Richard, Sundar Jagannath, Hearn Jay Cho, et al.
Frontiers in Immunology|December 1, 2018
Blood Transfusion Management for Patients Treated With Anti-CD38 Monoclonal AntibodiesGuido Lancman, Suzanne Arinsburg, Jeffrey Jhang, et al.
Expert Review of Hematology|August 1, 2020
Immunomodulatory drug- and proteasome inhibitor-backbone regimens in the treatment of relapsed multiple myeloma: an evidence-based reviewLarysa Sanchez, Kevin Barley, Joshua Richter, et al.
Therapeutic Advances in Hematology|February 22, 2021
Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myelomaLarysa Sanchez, Joshua Richter, Hearn Jay Cho, et al.
Clinical Advances in Hematology & Oncology : H&O|December 5, 2017
The effect of novel therapies in high-molecular-risk multiple myelomaGuido Lancman, Douglas Tremblay, Kevin Barley, et al.
Blood Advances|June 28, 2018
Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modelingVernon Wu, Erin Moshier, Siyang Leng, et al.
Blood Cancer Discovery|October 18, 2021
Bispecific Antibodies in Multiple Myeloma: Present and FutureGuido Lancman, Dahniel L Sastow, Hearn J Cho, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 15, 2021
Efficacy of Intravenous Immunoglobulin for Preventing Infections in Patients with Multiple MyelomaGuido Lancman, Katleen Lozada, Nida Athar, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 15, 2020
Timing of Autologous Stem Cell Transplantation for Multiple Myeloma in the Era of Current TherapiesSiyang Leng, Erin Moshier, Douglas Tremblay, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 18, 2021
Optimal Supportive Care With Selinexor Improves Outcomes in Patients With Relapsed/Refractory Multiple MyelomaAjai Chari, Erika Florendo, Ines Stefania Mancia, et al.
Pageof 5